Get a glimpse into our company and investor data—powered by the PitchBook Platform
Provider of biomimetic anti-angiogenic and anti-lymphangiogenic peptides created to treat ocular diseases. The company develops biomimetic anti-angiogenic and anti-lymphangiogenic peptides for indications in ophthalmology, oncology and for other angiogenesi and lymphangiogenesis-dependent diseases enabling patients and doctors to better treat ocular ailments.
You’re viewing a free company profile from the PitchBook Platform. To explore AsclepiX Therapeutics’s full profile, request a free trial.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Later Stage VC | 17-Jun-2019 | $5M | 00.00 | Completed | Generating Revenue | |
6. Grant | 01-Jan-2017 | 00.000 | 00000 | Completed | Generating Revenue | |
5. Convertible Debt | 20-Jul-2016 | 00000 | 00000 | Completed | Generating Revenue | |
4. Grant | 01-Sep-2015 | 00000 | Completed | Generating Revenue | ||
3. Grant | 24-Jul-2014 | 00.000 | Completed | Generating Revenue | ||
2. Accelerator/Incubator | 25-Jun-2014 | Completed | Generating Revenue | |||
1. Grant | 15-Jun-2013 | $100K | Completed | Generating Revenue |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
---|---|---|---|---|---|---|
Barer & Son Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
Piedmont Capital Partners | Merchant Banking Firm | Minority | 000 0000 | 000000 0 | ||
Rapha Capital Management | Corporation | Minority | 000 0000 | 000000 0 | ||
Salem Partners | Investment Bank | Minority | 000 0000 | 000000 0 | ||
TCP Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 |
Name | Representing | Role | Since | Contact Info |
---|---|---|---|---|
Wendy Perrow | AsclepiX Therapeutics | Chief Executive Officer & Board Member | 000 0000 |